Protagonist Therapeutics, Inc Increase (Decrease) in Contract with Customer, Asset
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Contract with Customer, Asset of $3.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-08-05
- Protagonist Therapeutics, Inc increase (decrease) in contract with customer, asset for the quarter ending 2025-06-30 was -$538.00K.
- Protagonist Therapeutics, Inc increase (decrease) in contract with customer, asset for the quarter ending 2025-03-31 was $22.82M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month |
|---|---|---|
| 2026-06-30 | $3.37M 10-Q · filed 2026-08-05 | |
| 2025-06-30 | -$538.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $22.29M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $22.82M 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |